Health Care • Biotechnology: Pharmaceutical Preparations
$8.46 ▼ -0.04
(-0.47%)
MKT CAP: $2.20B • VOL: 1.39M
52W L $3 52W H $9
MRVI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $185.7M | $259.2M | $288.9M |
| YoY Revenue Growth % | -28.3% | -10.3% | — |
| Gross Profit | $34.0M | $108.3M | — |
| Gross Margin % | 18.3% | 41.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$215.3M | -$235.6M | -$31.6M |
| Operating Margin % | -80.0% | -80.0% | -11.0% |
| Net Income (GAAP) | -$130.8M | -$144.8M | -$138.4M |
| EBITDA (Normalized) | -$204.7M | -$211.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$57.6M | $7.5M | $126.2M |
| Capital Expenditures (CapEx) | $13.1M | $29.7M | — |
| Free Cash Flow (FCF) | -$70.7M | -$22.2M | $126.2M |
| FCF Margin % | -38.1% | -8.6% | 43.7% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $216.9M | $322.4M | — |
| Total Debt (Short + Long Term) | $286.3M | $290.5M | — |
| Total Stockholders' Equity | $212.4M | $325.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MRVI.